CADL Stock Price, Candel Therapeutics, . Quote, Chart

Market Summary

USD10.07+0.48

Delayedas of 08 May 2024, 12:54 pm

5.01%

CADL Stock Price

View Fullscreen

CADL RSI Chart

CADL Valuation

Market Cap

281.4M

Price/Earnings (Trailing)

-7.42

Price/Sales (Trailing)

2.1K

Price/Free Cashflow

-8.11

CADL Price/Sales (Trailing)

CADL Profitability

Return on Equity

-297.68%

Return on Assets

-92.08%

Free Cashflow Yield

-12.33%

CADL Fundamentals

CADL Revenue

Revenue (TTM)

124.5K

CADL Earnings

Earnings (TTM)

-37.9M

Earnings Growth (Yr)

-118.28%

Earnings Growth (Qtr)

-31.54%

Breaking Down CADL Revenue

52 Week Range

10.31

(Low)(High)

Last 7 days

36.0%

Last 30 days

44.4%

Last 90 days

667.2%

Trailing 12 Months

484.8%

How does CADL drawdown profile look like?

CADL Financial Health

Current Ratio

2.59

Debt/Equity

0.04

Debt/Cashflow

-61.15

CADL Investor Care

Shares Dilution (1Y)

1.48%

Diluted EPS (TTM)

-1.31

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2022	124.5K	124.5K	124.5K	124.5K
2021	124.9K	124.8K	124.6K	124.5K
2020	0	0	0	125.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Candel Therapeutics, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Nov 28, 2023	tyagarajan seshu	sold (taxes)	-15,595	0.9	-17,328	chief technology officer
Nov 28, 2023	barone francesca	sold (taxes)	-17,773	0.9	-19,748	chief scientific officer
Nov 28, 2023	tak paul peter	sold (taxes)	-39,098	0.9	-43,443	chief executive officer
Nov 28, 2023	nichols william garrett	sold (taxes)	-10,957	0.9	-12,175	chief medical officer
Nov 28, 2023	amello jason	sold (taxes)	-18,137	0.9	-20,153	chief financial officer
Nov 26, 2023	tyagarajan seshu	acquired	-	-	104,516	chief technology officer
Nov 26, 2023	barone francesca	acquired	-	-	112,790	chief scientific officer
Nov 26, 2023	tak paul peter	acquired	-	-	180,108	chief executive officer
Nov 26, 2023	nichols william garrett	acquired	-	-	88,822	chief medical officer
Nov 26, 2023	amello jason	acquired	-	-	125,717	chief financial officer

Which funds bought or sold CADL recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
Apr 29, 2024	COMMONWEALTH EQUITY SERVICES, LLC	new	-	22,000	22,000	-%
Mar 11, 2024	VANGUARD GROUP INC	added	5.37	254,108	625,851	-%
Feb 14, 2024	STATE STREET CORP	unchanged	-	14,904	40,572	-%
Feb 14, 2024	BANK OF AMERICA CORP /DE/	new	-	26.00	26.00	-%
Feb 14, 2024	Northpond Ventures, LLC	unchanged	-	1,064,370	2,844,770	13.54%
Feb 14, 2024	TWO SIGMA SECURITIES, LLC	new	-	24,270	24,270	-%
Feb 14, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	unchanged	-	71,602	194,915	-%
Feb 14, 2024	Royal Bank of Canada	reduced	-90.2	-	-	-%

Are Funds Buying or Selling CADL?

Are funds buying CADL calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CADL

No. of Funds

Unveiling Candel Therapeutics, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Feb 14, 2022	northpond ventures, lp	5.9%	1,685,215	SC 13G
Feb 14, 2022	manning paul b	13.6%	4,073,316	SC 13D
Feb 09, 2022	fmr llc	-	0	SC 13G

Recent SEC filings of Candel Therapeutics, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 25, 2024	8-K	Current Report
Apr 25, 2024	10-K/A	Annual Report
Apr 11, 2024	8-K	Current Report
Apr 09, 2024	8-K	Current Report
Apr 04, 2024	8-K	Current Report
Mar 28, 2024	S-8	Employee Benefits Plan
Mar 28, 2024	8-K	Current Report
Mar 28, 2024	10-K	Annual Report
Mar 06, 2024	8-K	Current Report
Feb 13, 2024	8-K	Current Report

Peers (Alternatives to Candel Therapeutics, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	46.4B	6.8B	17.66%	-8.12%	-7.77	6.77	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.5B	2.0B	0.45%	-26.53%	-58.76	9.74	75.20%	68.82%
BMRN	15.7B	2.5B	-4.99%	-13.89%	76.35	6.35	13.74%	186.89%
INCY	12.2B	3.8B	-1.56%	-17.34%	16.38	3.24	8.58%	129.81%
MID-CAP
APLS	5.3B	524.1M	-21.34%	-51.87%	-12.77	10.17	394.93%	39.61%
BBIO	5.2B	107.9M	-1.17%	105.40%	-9.51	48.09	54.84%	-28.31%
AXSM	3.7B	251.0M	6.53%	-0.98%	-12.33	14.56	73.58%	-86.73%
ARWR	3.1B	240.7M	-3.03%	-38.20%	-10.44	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-4.16%	-19.91%	-46.38	3.91	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-0.20%	-12.84%	24.99	4.48	85.90%	-14.05%
NVAX	645.2M	983.7M	4.30%	-38.12%	-1.18	0.66	-50.36%	17.16%
CRBP	424.2M	881.7K	-0.70%	291.81%	-12.56	481.06	-77.61%	33.36%
INO	259.6M	4.9M	-5.85%	11.55%	-1.92	53.35	-54.97%	51.71%
IBIO	7.1M	2.1M	-3.32%	88.89%	-0.26	2.14	-13.45%	66.37%

Candel Therapeutics, Inc. News

Latest updates

Candel Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)											(In Thousands)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2
Revenue	1.6%	32.00	31.00	31.00	31.00	32.00	31.00	31.00	31.00	31.00	31.00	94.00
Operating Expenses	-8.7%	8,133	8,912	8,784	9,017	7,771	8,060	5,332	4,688	-	2,780	2,650
S&GA Expenses	-10.6%	3,161	3,536	3,762	3,600	3,910	2,795	2,040	1,935	-	967	855
R&D Expenses	-7.5%	4,972	5,376	5,022	5,417	3,861	5,265	3,292	2,753	-	1,813	1,795
Interest Expenses	45.2%	754	519	435	-175	-	-	-	-	-	-	-
Income Taxes	17.4%	27.00	23.00	48.00	85.00	1.00	7.00	15.00	6.00	-	-	-
Net Income	41.5%	-5,083	-8,688	-4,149	-874	1,596	-16,162	-17,080	-4,478	-	-2,554	-2,876
Net Income Margin	-55.1%	-150.96*	-97.31*	-157.34*	-261.20*	-290.15*	-141.87*	-141.72*	-141.58*	-141.44*	-	-
Free Cashflow	25.4%	-7,161	-9,599	-7,732	-8,224	-5,742	-7,286	-5,169	-5,856	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet												(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4
Assets	-17.7%	41.00	50.00	59.00	67.00	78.00	85.00	93.00	102	89.00	96.00	31.00	38.00
Current Assets	-18.4%	37.00	45.00	53.00	62.00	72.00	79.00	87.00	96.00	85.00	91.00	24.00	35.00
Cash Equivalents	-17.6%	35.00	43.00	52.00	59.00	70.00	77.00	87.00	95.00	83.00	89.00	25.00	35.00
Net PPE	-12.8%	3.00	4.00	4.00	4.00	4.00	5.00	5.00	4.00	4.00	5.00	5.00	3.00
Liabilities	5.2%	28.00	27.00	28.00	28.00	30.00	33.00	33.00	38.00	25.00	33.00	25.00	13.00
Current Liabilities	37.3%	14.00	10.00	8.00	5.00	6.00	6.00	6.00	5.00	5.00	4.00	4.00	5.00
Long Term Debt	-	-	-	-	-	-	-	-	-	1.00	1.00	1.00	0.00
LT Debt, Current	45.8%	9.00	6.00	4.00	1.00	-	-	-	-	-	-	-	-
Shareholder's Equity	-44.6%	13.00	23.00	31.00	40.00	48.00	52.00	60.00	64.00	64.00	63.00	-	-
Retained Earnings	-8.8%	-137	-125	-117	-107	-99.09	-94.00	-85.30	-81.17	-80.29	-81.89	-65.73	-44.17
Additional Paid-In Capital	0.5%	150	149	148	148	147	146	146	145	144	145	22.00	20.00
Shares Outstanding	0.6%	29.00	29.00	29.00	29.00	29.00	29.00	29.00	29.00	29.00	23.00	12.00	12.00
Float	-	-	-	28.00	-	-	-	72.00	-	-	-	107	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)															(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2
Cashflow From Operations	15.7%	-7,422	-8,808	-7,195	-10,819	-6,885	-9,384	-7,097	-8,053	-5,238	-6,894	-4,459	-5,627	-	-	-
Share Based Compensation	36.9%	939	686	733	733	634	743	438	492	-446	1,909	1,069	431	-	-	-
Cashflow From Investing	73.8%	-27.00	-103	-169	19.00	-276	-215	-635	-171	-504	-392	-710	-229	-	-	-
Cashflow From Financing	-	-	-	-	-	36.00	-	22.00	19,916	-	71,355	333	112	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

CADL Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Research and development service revenue, related party		$ 125
Operating expenses:
Research and development	$ 24,506	20,787
General and administrative	13,885	14,060
Total operating expenses	38,391	34,847
Loss from operations	(38,391)	(34,722)
Other income (expense):
Grant income		48
Interest income	2,081	1,218
Interest expense	(2,595)	(1,708)
Change in fair value of warrant liability	966	16,370
Total other income (expense), net	452	15,928
Net loss and comprehensive loss	$ (37,939)	$ (18,794)
Net loss per share - basic	$ (1.31)	$ (0.65)
Net loss per share - diluted	$ (1.31)	$ (0.65)
Weighted-average common shares outstanding, basic	28,935,289	28,823,480
Weighted-average common shares outstanding, diluted	28,935,289	28,823,480

CADL Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 35,413	$ 70,058
Prepaid expenses and other current assets	1,384	1,887
Total current assets	36,797	71,945
Fixed assets, net	3,206	4,424
Lease right of use assets	816	1,056
Restricted cash	266	266
Other assets	116
Total assets	41,201	77,691
Current liabilities:
Accounts payable	422	380
Accrued expenses	4,356	4,723
Current portion of term loan payable to a bank	8,893
Current portion of lease liability	513	464
Other current liabilities		48
Total current liabilities	14,184	5,615
Deferred revenue		144
Term loan payable to a bank	11,632	20,202
Other long-term debt	751	648
Lease liability, net of current portion	973	1,486
Warrant liability	916	1,882
Total liabilities	28,456	29,977
Commitments and contingencies (Note 15)
Stockholders' equity
Preferred stock, $0.01 par value; 10,000,000 shares authorized at December 31, 2023 and 2022; no shares issued or outstanding at December 31, 2023 and 2022, respectively.
Common stock, $0.01 par value; 150,000,000 shares authorized at December 31, 2023 and 2022; 29,213,627 and 29,042,418 shares issued at December 31, 2023 and 2022, respectively; and 29,091,019 and 28,919,810 shares outstanding at December 31, 2023 and 2022, respectively.	290	290
Treasury stock (at cost)	(448)	(448)
Additional paid-in capital	149,931	146,961
Accumulated deficit	(137,028)	(99,089)
Total stockholders' equity	12,745	47,714
Total liabilities and stockholders' equity	$ 41,201	$ 77,691

About Candel Therapeutics, Inc.

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is based in Needham, Massachusetts.

CEO	Dr. Paul-Peter Tak FMEDSCI, M.D., Ph.D.
WEBSITE	candeltx.com
INDUSTRY	Biotechnology
EMPLOYEES	76

Candel Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Candel Therapeutics, Inc.? What does CADL stand for in stocks?

CADL is the stock ticker symbol of Candel Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Candel Therapeutics, Inc. (CADL)?

As of Tue May 07 2024, market cap of Candel Therapeutics, Inc. is 281.44 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CADL stock?

You can check CADL's fair value in chart for subscribers.

What is the fair value of CADL stock?

You can check CADL's fair value in chart for subscribers. The fair value of Candel Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Candel Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CADL so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Candel Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether CADL is over valued or under valued. Whether Candel Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Candel Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CADL.

What is Candel Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue May 07 2024, CADL's PE ratio (Price to Earnings) is -7.42 and Price to Sales (PS) ratio is 2.13 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CADL PE ratio will change depending on the future growth rate expectations of investors.